NASDAQ: BRTXBiorestorative Therapies Inc Stock
$1.40-0.06 (-4.11%)
Updated Nov 6, 2025
BRTX Price
$1.40
Fair Value Price
N/A
Market Cap
$11.17M
52 Week Low
$1.19
52 Week High
$2.55
P/E
-1.1x
P/B
2.31x
P/S
24.06x
PEG
N/A
Dividend Yield
N/A
Revenue
$605.20k
Earnings
-$10.72M
Gross Margin
94.5%
Operating Margin
-1,771.91%
Profit Margin
-1,771.9%
Debt to Equity
0.76
Operating Cash Flow
-$10M
Beta
0.84
Next Earnings
Nov 18, 2025
Ex-Dividend
N/A
Next Dividend
N/A
BRTX Overview
BioRestorative Therapies Inc is a biotechnology company developing therapies using cell and tissue protocols, mostly involving non-embryonic stem cells. The company's Disc/Spine Program includesBRTX-100, a cell therapy candidate formulated from stem cells collected from the patient's bone marrow. Its Metabolic Program is developing a cell-based therapy to target obesity and metabolic disorders using brown adipose-derived stem cells. BioRestorative Therapies was founded in 1997 and is headquartered in Melville, New York.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine BRTX's potential to beat the market
- BRTX doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
BRTX
RankedUnranked of 481
RankedUnranked of 481
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $7.33 | A | |
| $105.20 | A | |
| $134.05 | A |
Be the first to know about important BRTX news, forecast changes, insider trades & much more!
BRTX News
Overview
Due Diligence Score
–
Industry Average (23)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how BRTX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
BRTX is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
BRTX is good value based on its book value relative to its share price (2.31x), compared to the US Biotechnology industry average (4.85x)
P/B vs Industry Valuation
BRTX is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more BRTX due diligence checks available for Premium users.
Valuation
BRTX price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-1.1x
Industry
252.41x
Market
45.67x
BRTX price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
2.31x
Industry
4.85x
BRTX is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
BRTX's financial health
Profit margin
Revenue
$303.3k
Net Income
-$2.7M
Profit Margin
-875.8%
BRTX's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
BRTX's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$8.5M
Liabilities
$3.7M
Debt to equity
0.76
BRTX's short-term assets ($7.60M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
BRTX's short-term assets ($7.60M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
BRTX's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
BRTX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$2.7M
Investing
$2.1M
Financing
$888.1k
BRTX's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
BRTX vs Biotech Stocks
Biorestorative Therapies Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.